Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: High-Throughput Libraries and Machine Learning-Guided Optimization of Retron Editrons

PROVIDER: PRJNA1121319 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29321100.fastq.gz	Fastqsanger.gz
	SRR29321101.fastq.gz	Fastqsanger.gz
	SRR29321102.fastq.gz	Fastqsanger.gz
	SRR29321103.fastq.gz	Fastqsanger.gz
	SRR29321104.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 192

Similar Datasets

Project description:High diversity gene libraries facilitate machine learning guided exploration of fluorescent protein sequence space

| PRJNA1282861 | ENA

Project description:Machine-learning-guided aptamer discovery

| PRJNA672779 | ENA

Human Gut microbiome

Project description:High-throughput microbial culturomics using automation and machine learning

| PRJNA745993 | ENA

In silico nano-dissection: defining cell type specificity at transcriptional level in human disease (tubulointerstitium)

Project description:To identify genes with cell-lineage-specific expression not accessible by experimental micro-dissection, we developed a genome-scale iterative method, in-silico nano-dissection, which leverages high-throughput functional-genomics data from tissue homogenates using a machine-learning framework. This study applied nano-dissection to chronic kidney disease and identified transcripts specific to podocytes, key cells in the glomerular filter responsible for hereditary proteinuric syndromes and acquired CKD. In-silico prediction accuracy exceeded predictions derived from fluorescence-tagged-murine podocytes, identified genes recently implicated in hereditary glomerular disease and predicted genes significantly correlated with kidney function. The nano-dissection method is broadly applicable to define lineage specificity in many functional and disease contexts. We applied a machine-learning framework on high-throughput gene expression data from human kidney biopsy tissue homogenates and predict novel podocyte-specific genes. The prediction was validated by Human Protein Atlas at protein level. Prediction accuracy was compared with predictions derived from experimental approach using fluorescence-tagged-murine podocytes.

2013-08-06 | E-GEOD-47184 | biostudies-arrayexpress

In silico nano-dissection: defining cell type specificity at transcriptional level in human disease (glomeruli)

2013-08-06 | E-GEOD-47183 | biostudies-arrayexpress

Project description:Functional screening of DNAJB6 for machine learning-guided protein engineering

| PRJNA1240288 | ENA

Project description:Meta Learning Addresses Noisy and Under Labeled Data in Machine Learning-Guided Antibody Engineering

| PRJNA1029889 | ENA

Project description:Machine learning optimization of peptides for presentation by class II MHCs

| PRJNA708266 | ENA

Functional Optimization of Designer Cardiac Organoids Enabled by Machine Learning Techniques

Project description:Functional Optimization of Designer Cardiac Organoids Enabled by Machine Learning Techniques

| PRJNA1111511 | ENA

A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules (ChIP-Seq)

Project description:High-throughput screening and gene signature analyses frequently identify lead therapeutic compounds with unknown modes of action (MoAs), and the resulting uncertainties can lead to the failure of clinical trials. We developed a multi-omics approach for uncovering MoAs through an interpretable machine learning model of the effects of compounds on transcriptomic, epigenomic, metabolomic, and proteomic data. We applied this approach to examine compounds with beneficial effects in models of Huntington’s disease, finding common MoAs for previously unrelated compounds that were not predicted based on similarities in the compounds’ structures, connectivity scores, or binding targets. We experimentally validated two such disease-relevant MoAs, autophagy activation and bioenergetics manipulation. This interpretable machine learning approach can be used to find and evaluate MoAs in future drug development efforts.

2020-01-22 | GSE129141 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data